Chinese vaccine granted patent for authorisation

China is now the newest country in the world following the footsteps of Russia to register its novel vaccine for Covid-19 produced by CanSino biopharmaceutical firm.

Chinese authorities granted the patent after studies proved that the vaccine prototype concurred with creative and intellectual property bases set by Beijing officials.

The Chinese vaccine titled Ad5-nCOV was first submitted for approvals in the month of March makes use of a version of a common cold virus strain to transport genetic material into the human body and train it to prevent further infection and spike up antibodies in the host body,  This vaccine is amongst the 5 vaccines being locally made and developed in China. Scientists were able to observe positive immunity and increased T-cell production levels in the body post phase I and II trials.

There are 3 other candidates globally, who have reached phase III of testing including Oxford University – AstraZeneca, Pfizer-Biotech, and Moderna Therapeutics Inc. Finalisation and completion of phase III trials are crucial before a vaccine is approved for public use. The lack of necessary testing with the Russian vaccine has shrouded the experimental vaccine in a pool of controversy.

Similar clinical trials have also been lined-up to be conducted in Mexico, Saudi Arabia, Brazil, and Chile.